Why Viking Stock Jumped On Obesity Data. Novo Falls.
Viking Therapeutics shares jumped 36% after the company released positive data for its GLP-1/GIP dual agonist obesity drug. The candidate exceeded expectations in a small study, specifically regarding once-a-month maintenance dosing. While the data caused Viking stock to skyrocket, competitors Eli Lilly and Novo Nordisk saw their shares fall. However, Viking later faced a selloff after pricing an upsized financing deal at a 16% discount from Wednesday's closing price.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Viking Therapeutics stock increased 36% following the release of obesity drug data.
- ✓ The company's GLP-1/GIP dual agonist exceeded expectations in a small study.
- ✓ Viking's weight loss candidate showed positive data for once-a-month maintenance.
- ✓ Shares of Eli Lilly and Novo Nordisk fell as Viking stock rose.
What changed
Viking Therapeutics released maintenance data for its weight loss candidate and subsequently announced an upsized financing deal at a discount.
Live updates
-
Viking Therapeutics Stock Surges on Obesity Drug Maintenance Data
Viking Therapeutics shares jumped 36% after the company released positive data for its GLP-1/GIP dual agonist obesity drug. The candidate exceeded expectations in a small study, specifically regarding once-a-month maintenance dosing. While the data caused Viking stock to skyrocket, competitors Eli Lilly and Novo Nordisk saw their shares fall. However, Viking later faced a selloff after pricing an upsized financing deal at a 16% discount from Wednesday's closing price.
Why it matters
The obesity drug market is currently dominated by GLP-1 agonists from Novo Nordisk and Eli Lilly. Viking's dual agonist approach aims to challenge this dominance by improving dosing frequency and efficacy. Maintenance data is critical for long-term patient adherence in weight loss treatments.
What is confirmed
- Viking Therapeutics stock increased 36% following the release of obesity drug data.
- The company's GLP-1/GIP dual agonist exceeded expectations in a small study.
- Viking's weight loss candidate showed positive data for once-a-month maintenance.
- Shares of Eli Lilly and Novo Nordisk fell as Viking stock rose.
- Viking priced an upsized financing deal at a 16% discount from Wednesday's closing price.
What to watch next
- Results from larger clinical trials for the GLP-1/GIP dual agonist
- Further analyst target price adjustments from firms like Oppenheimer
confidence 95%Sources used for this update (8)
- Investor's Business Daily — Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
- endpoints.news — Viking touts once-a-month maintenance data for its weight loss candidate
- Barron's — Novo and Lilly Challenged: Viking Stock Surges on Weight-Loss Drug Trial
- BioSpace — Viking achieves ‘maintenance trifecta’ as GLP-1/GIP dual agonist exceeds expectations
- Bloomberg.com — Viking Soars as Obesity Shot Helps Cut Weight in Small Study
- Yahoo Finance — Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
- Yahoo Finance — VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
- finance.yahoo.com — VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community